July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG)
Author Affiliations & Notes
  • Kelly A Leary
    Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Kuan-Ting Lin
    Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Juan P. Steibel
    Animal Science, Michigan State University, East Lansing, Michigan, United States
    Fisheries & Wildlife, Michigan State Univeristy, East Lansing, Michigan, United States
  • Christine Harman
    Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Andras M Komaromy
    Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Footnotes
    Commercial Relationships   Kelly Leary, None; Kuan-Ting Lin, None; Juan Steibel, None; Christine Harman, None; Andras Komaromy, None
  • Footnotes
    Support  NIH grant R01-EY025752 and MSU-CVM Endowed Research Funds
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3784. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kelly A Leary, Kuan-Ting Lin, Juan P. Steibel, Christine Harman, Andras M Komaromy; Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG). Invest. Ophthalmol. Vis. Sci. 2019;60(9):3784. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Netarsudil 0.02% ophthalmic solution (Rhopressa™; Aerie Pharmaceutical) is a Rho kinase inhibitor recently approved by the FDA for lowering intraocular pressure (IOP) in patients with OAG or ocular hypertension. The purpose of this study was to evaluate for the first time its efficacy and safety in normal and OAG-affected canines, an important translational large animal species.

Methods : Testing was performed in 5 normal and 5 ADAMTS10-OAG dogs between 1.0-2.7 yrs of age. In each dog, the left or right eye was randomly selected for netarsudil treatment. Contralateral eyes were sham treated with balanced salt solution (BSS). Following a 1-wk baseline period, dogs were treated once daily (q24h) during wk 2, and twice daily (q12h) during wk 3; wk 4 served as washout period. Efficacy was evaluated and compared between treated and sham eyes within each group by diurnal IOP and pupil measurements. Safety measures were assessed by routine ophthalmic examination, gonioscopy and pachymetry, and included conjunctival hyperemia, comfort level, and central corneal thickness (CCT). Statistical analysis was performed to compare IOP, pupil diameter, conjunctival hyperemia, CCT for treated vs. sham eyes within each group.

Results : Baseline IOPs were 18.5±0.5mmHg (mean±SEM) for normal and 27.8±1.0 mmHg for OAG dogs. Even though mean IOPs were lower with netarsudil vs. sham, the difference was neither significant nor clinically relevant with q24h and q12h administration (q24h-normal: sham 16.0±0.3 mmHg vs. treatment 15.3±0.5 mmHg; q24hr-OAG: sham 26.1± 0.5 mmHg vs. treatment 26.0± 0.6 mmHg; q12hr-normal: sham 15.4±0.4 mmHg vs. treatment 14.4±0.4 mmHg; q12hr-OAG: sham 26.3±3.3 mmHg vs. treatment 25.4±1.0 mmHg). Netarsudil administration resulted in significant, moderate to severe conjunctival hyperemia in all treated eyes; this was more severe in the OAG group (p<0.001). No other adverse effects were observed.

Conclusions : Except for a 100% incidence of conjunctival hyperemia, topically administered netarsudil 0.02% ophthalmic solution was well tolerated by dogs. The treatment did not result in a significant reduction of IOP in normal and OAG-affected dogs. It remains to be shown if netarsudil has a synergistic effect in canines when combined with other compounds such as latanoprost (Roclatan™; Aerie Pharmaceutical).

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×